Switch theme
Sign up to access all valuation multiples
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
2017
37K+
LTM Revenue $11.7B
LTM EBITDA $585M
$6.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BrightSpring Health has a last 12-month revenue (LTM) of $11.7B and a last 12-month EBITDA of $585M.
In the most recent fiscal year, BrightSpring Health achieved revenue of $11.3B and an EBITDA of $398M.
BrightSpring Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BrightSpring Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.7B | XXX | $11.3B | XXX | XXX | XXX |
| Gross Profit | $1.5B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA | $585M | XXX | $398M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $371M | XXX | $206M | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Profit | $45.7M | XXX | -$18.1M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BrightSpring Health's stock price is $24.
BrightSpring Health has current market cap of $4.1B, and EV of $6.8B.
See BrightSpring Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.8B | $4.1B | XXX | XXX | XXX | XXX | $0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BrightSpring Health has market cap of $4.1B and EV of $6.8B.
BrightSpring Health's trades at 0.6x EV/Revenue multiple, and 17.1x EV/EBITDA.
Equity research analysts estimate BrightSpring Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BrightSpring Health has a P/E ratio of 90.8x.
See valuation multiples for BrightSpring Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| EV (current) | $6.8B | XXX | $6.8B | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 11.7x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBIT | 18.4x | XXX | 33.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 90.8x | XXX | -229.7x | XXX | XXX | XXX |
| EV/FCF | 99.4x | XXX | -119.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBrightSpring Health's last 12 month revenue growth is 10%
BrightSpring Health's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $37K for the same period.
BrightSpring Health's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BrightSpring Health's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BrightSpring Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | 14% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $37K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BrightSpring Health acquired XXX companies to date.
Last acquisition by BrightSpring Health was XXXXXXXX, XXXXX XXXXX XXXXXX . BrightSpring Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BrightSpring Health founded? | BrightSpring Health was founded in 2017. |
| Where is BrightSpring Health headquartered? | BrightSpring Health is headquartered in United States of America. |
| How many employees does BrightSpring Health have? | As of today, BrightSpring Health has 37K+ employees. |
| Who is the CEO of BrightSpring Health? | BrightSpring Health's CEO is Mr. Jon B. Rousseau. |
| Is BrightSpring Health publicy listed? | Yes, BrightSpring Health is a public company listed on NAS. |
| What is the stock symbol of BrightSpring Health? | BrightSpring Health trades under BTSG ticker. |
| When did BrightSpring Health go public? | BrightSpring Health went public in 2024. |
| Who are competitors of BrightSpring Health? | Similar companies to BrightSpring Health include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of BrightSpring Health? | BrightSpring Health's current market cap is $4.1B |
| What is the current revenue of BrightSpring Health? | BrightSpring Health's last 12 months revenue is $11.7B. |
| What is the current revenue growth of BrightSpring Health? | BrightSpring Health revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of BrightSpring Health? | Current revenue multiple of BrightSpring Health is 0.6x. |
| Is BrightSpring Health profitable? | Yes, BrightSpring Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BrightSpring Health? | BrightSpring Health's last 12 months EBITDA is $585M. |
| What is BrightSpring Health's EBITDA margin? | BrightSpring Health's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of BrightSpring Health? | Current EBITDA multiple of BrightSpring Health is 11.7x. |
| What is the current FCF of BrightSpring Health? | BrightSpring Health's last 12 months FCF is $68.5M. |
| What is BrightSpring Health's FCF margin? | BrightSpring Health's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of BrightSpring Health? | Current FCF multiple of BrightSpring Health is 99.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
